Current perspectives on mesenchymal stromal cell therapy for graft versus host disease

Friedenstein AJ, Petrakova KV, Kurolesova AI, Frolova GP. Heterotopic of bone marrow. Analysis of precursor cells for osteogenic and hematopoietic tissues. Transplantation. 1968;6:230–47.

Article  CAS  PubMed  Google Scholar 

Soliman H, Theret M, Scott W, Hill L, Underhill TM, Hinz B, et al. Multipotent stromal cells: One name, multiple identities. Cell Stem Cell. 2021;28:1690–707.

Article  CAS  PubMed  Google Scholar 

Krampera M, Le Blanc K. Mesenchymal stromal cells: Putative microenvironmental modulators become cell therapy. Cell Stem Cell. 2021;28:1708–25.

Article  CAS  PubMed  Google Scholar 

Zhao K, Lin R, Fan Z, Chen X, Wang Y, Huang F, et al. Mesenchymal stromal cells plus basiliximab, calcineurin inhibitor as treatment of steroid-resistant acute graft-versus-host disease: a multicenter, randomized, phase 3, open-label trial. J Hematol Oncol. 2022;15:22.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Socié G, Ritz J. Current issues in chronic graft-versus-host disease. Blood. 2014;124:374–84.

Article  PubMed  PubMed Central  Google Scholar 

Lee SJ. Classification systems for chronic graft-versus-host disease. Blood. 2017;129:30–37.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Przepiorka D, Weisdorf D, Martin P, Klingemann HG, Beatty P, Hows J, et al. 1994 Consensus Conference on Acute GVHD Grading. Bone Marrow Transpl. 1995;15:825–8.

CAS  Google Scholar 

MacMillan ML, Robin M, Harris AC, DeFor TE, Martin PJ, Alousi A, et al. A refined risk score for acute graft-versus-host disease that predicts response to initial therapy, survival, and transplant-related mortality. Biol Blood Marrow Transpl. 2015;21:761–7.

Article  Google Scholar 

MacDonald KP, Hill GR, Blazar BR. Chronic graft-versus-host disease: biological insights from preclinical and clinical studies. Blood. 2017;129:13–21.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Arai S, Arora M, Wang T, Spellman SR, He W, Couriel DR, et al. Increasing incidence of chronic graft-versus-host disease in allogeneic transplantation: a report from the Center for International Blood and Marrow Transplant Research. Biol Blood Marrow Transpl. 2015;21:266–74.

Article  Google Scholar 

Wolff D, Greinix H, Lee SJ, Gooley T, Paczesny S, Pavletic S, et al. Biomarkers in chronic graft-versus-host disease: quo vadis? Bone Marrow Transpl. 2018;53:832–7.

Article  CAS  Google Scholar 

Goklemez S, Im AP, Cao L, Pirsl F, Steinberg SM, Curtis LM, et al. Clinical characteristics and cytokine biomarkers in patients with chronic graft-vs-host disease persisting seven or more years after diagnosis. Am J Hematol. 2020;95:387–94.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Subburaj D, Ng B, Kariminia A, Abdossamadi S, Lauener M, Nemecek ER, et al. Metabolomic identification of α-ketoglutaric acid elevation in pediatric chronic graft-versus-host disease. Blood. 2022;139:287–99.

Article  CAS  PubMed  Google Scholar 

Cuvelier, GDE, Ng, B, Abdossamadi, S, Nemecek, ER, Melton, A, Kitko, CL et al. A diagnostic classifier for pediatric chronic graft-versus-host disease: results of the ABLE / PBMTC 1202 study. Blood Adv Bloodadvances. 2022007715 (2022) https://doi.org/10.1182/bloodadvances.2022007715.

Martin PJ, Rizzo JD, Wingard JR, Ballen K, Curtin PT, Cutler C, et al. First- and second-line systemic treatment of acute graft-versus-host disease: recommendations of the American Society of Blood and Marrow Transplantation. Biol Blood Marrow Transpl. 2012;18:1150–63.

Article  Google Scholar 

Nassereddine S, Rafei H, Elbahesh E, Tabbara I. Acute Graft. Anticancer Res. 2017;37:1547–55.

Article  CAS  PubMed  Google Scholar 

MacMillan ML, DeFor TE, Weisdorf DJ. The best endpoint for acute GVHD treatment trials. Blood. 2010;115:5412–7.

Article  CAS  PubMed  Google Scholar 

Srinagesh HK, Özbek U, Kapoor U, Ayuk F, Aziz M, Ben-David K, et al. The MAGIC algorithm probability is a validated response biomarker of treatment of acute graft-versus-host disease. Blood Adv. 2019;3:4034–42.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Castilla-Llorente C, Martin PJ, McDonald GB, Storer BE, Appelbaum FR, Deeg HJ, et al. Prognostic factors and outcomes of severe gastrointestinal GVHD after allogeneic hematopoietic cell transplantation. Bone Marrow Transpl. 2014;49:966–71.

Article  CAS  Google Scholar 

Filipovich AH, Weisdorf D, Pavletic S, Socie G, Wingard JR, Lee SJ, et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. Biol Blood Marrow Transpl. 2005;11:945–56.

Article  Google Scholar 

Jagasia MH, Greinix HT, Arora M, Williams KM, Wolff D, Cowen EW, et al. National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group report. Biol Blood Marrow Transpl. 2015;21:389–401.e1.

Article  Google Scholar 

Kitko CL, Pidala J, Schoemans HM, Lawitschka A, Flowers ME, Cowen EW, et al. National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: IIa. The 2020 Clinical Implementation and Early Diagnosis Working Group Report. Transpl Cell Ther. 2021;27:545–57.

Article  Google Scholar 

Martini DJ, Chen Y-B, DeFilipp Z. Recent FDA Approvals in the Treatment of Graft-Versus-Host Disease. Oncologist. 2022;27:685–93.

Article  PubMed  PubMed Central  Google Scholar 

Socié G, Vigouroux S, Yakoub-Agha I, Bay JO, Fürst S, Bilger K, et al. A phase 3 randomized trial comparing inolimomab vs usual care in steroid-resistant acute GVHD. Blood. 2017;129:643–9.

Article  PubMed  Google Scholar 

Macmillan ML, Couriel D, Weisdorf DJ, Schwab G, Havrilla N, Fleming TR, et al. A phase 2/3 multicenter randomized clinical trial of ABX-CBL versus ATG as secondary therapy for steroid-resistant acute graft-versus-host disease. Blood. 2007;109:2657–62.

Article  CAS  PubMed  Google Scholar 

Van Lint MT, Milone G, Leotta S, Uderzo C, Scimè R, Dallorso S, et al. Treatment of acute graft-versus-host disease with prednisolone: significant survival advantage for day +5 responders and no advantage for nonresponders receiving anti-thymocyte globulin. Blood. 2006;107:4177–81.

Article  PubMed  Google Scholar 

Wolff D, Schleuning M, von Harsdorf S, Bacher U, Gerbitz A, Stadler M, et al. Consensus Conference on Clinical Practice in Chronic GVHD: Second-Line Treatment of Chronic Graft-versus-Host Disease. Biol Blood Marrow Transpl. 2011;17:1–17.

Article  Google Scholar 

Miklos D, Cutler CS, Arora M, Waller EK, Jagasia M, Pusic I, et al. Ibrutinib for chronic graft-versus-host disease after failure of prior therapy. Blood. 2017;130:2243–50.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Cutler C, Lee SJ, Arai S, Rotta M, Zoghi B, Lazaryan A, et al. Belumosudil for chronic graft-versus-host disease after 2 or more prior lines of therapy: the ROCKstar Study. Blood. 2021;138:2278–89.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Jagasia M, Perales MA, Schroeder MA, Ali H, Shah NN, Chen YB, et al. Ruxolitinib for the treatment of steroid-refractory acute GVHD (REACH1): a multicenter, open-label phase 2 trial. Blood. 2020;135:1739–49.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Zeiser R, von Bubnoff N, Butler J, Mohty M, Niederwieser D, Or R, et al. Ruxolitinib for Glucocorticoid-Refractory Acute Graft-versus-Host Disease. N. Engl J Med. 2020;382:1800–10.

Article  PubMed  Google Scholar 

Zeiser R, Polverelli N, Ram R, Hashmi SK, Chakraverty R, Middeke JM, et al. Ruxolitinib for Glucocorticoid-Refractory Chronic Graft-versus-Host Disease. N. Engl J Med. 2021;385:228–38.

Article  CAS  PubMed  Google Scholar 

Lazarus HM, Haynesworth SE, Gerson SL, Rosenthal NS, Caplan AI. Ex vivo expansion and subsequent infusion of human bone marrow-derived stromal progenitor cells (mesenchymal progenitor cells): implications for therapeutic use. Bone Marrow Transpl. 1995;16:557–64.

CAS  Google Scholar 

Koç ON, Gerson SL, Cooper BW, Dyhouse SM, Haynesworth SE, Caplan AI, et al. Rapid hematopoietic recovery after coinfusion of autologous-blood stem cells and culture-expanded marrow mesenchymal stem cells in advanced breast cancer patients receiving high-dose chemotherapy. J Clin Oncol. 2000;18:307–16.

Article  PubMed  Google Scholar 

Le Blanc K, Rasmusson I, Sundberg B, Götherström C, Hassan M, Uzunel M, et al. Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells. Lancet. 2004;363:1439–41.

Article  PubMed  Google Scholar 

Ringdén O, Uzunel M, Rasmusson I, Remberger M, Sundberg B, Lönnies H, et al. Mesenchymal stem cells for treatment of therapy-resistant graft-versus-host disease. Transplantation. 2006;81:1390–7.

Article  PubMed  Google Scholar 

Le Blanc K, Frassoni F, Ball L, Locatelli F, Roelofs H, Lewis I, et al. Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase II study. Lancet. 2008;371:1579–86.

Article  PubMed  Google Scholar 

Pérez-Simon JA, López-Villar O, Andreu EJ, Rifón J, Muntion S, Diez Campelo M, et al. Mesenchymal stem cells expanded in vitro with human serum for the treatment of acute and chronic graft-versus-host disease: results of a phase I/II clinical trial. Haematologica. 2011;96:1072–6.

Article  PubMed  PubMed Central 

留言 (0)

沒有登入
gif